For over 30 years, delayed sleep phase disorder (DSPD) has been defined as a debilitating sleep condition. Recently, there is more awareness of DSPD in young people, yet considerable information is needed to understand its cause and treatment. This review describes the latest research findings describing the clinical features, cause, and treatment of DSPD.
INTRODUCTION
The second edition of the International Classification of Sleep Disorders (ICSD-2) and the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) concur that delayed sleep phase disorder (DSPD) is recognized as normal sleep that is significantly delayed in its timing with respect to the individual's desired sleep-onset and rising times [1, 2] . The ICSD-2 states that a person experiencing DSPD may fall asleep between 1 a.m. and 6 a.m. [1] , which creates significant difficulty in rising for work or for school in the morning. Sleeponset times may be moderated by age, culture, and whether the individual is still able to attend morning commitments (e.g., school) [3 & ,4 & ,5]. Seventeen percent of high school students report difficulty falling asleep before 2 a.m. at least three times per week, which is symptomatic for DSPD [4 & ]. Many adolescents throughout the world show a delayed sleep pattern [5] , but the sleep pattern is considered disordered when it significantly impacts upon an important area of the individual's functioning [1, 2] . The most affected area of functioning is school life, including frequently being late for school, nonschool attendance and dropout, oversleeping on school mornings, excessive sleepiness at school, chronic sleep reduction, and poor school perform- 6,7,8 & ]. Poor school performance has been more highly correlated with daytime sleepiness than sleep quality and duration [9] . Excessive sleepiness on school days is likely because of school-week sleep being restricted (e.g., range 5. ]. It is likely that the negative consequences of DSPD continue after the school years, as young adults with DSPD report significant disruptions in the aspects of work, family, and social life (Micic et al., in preparation) .
Estimates of DSPD prevalence range from 1 to 16% [1, 6] in adolescent populations, with estimates of delayed sleep timing (i.e., delayed sleep pattern without differential diagnosis) lying mid-way in the range ($8%) [4 & ]. Several behaviors have been identified in adolescents with DSPD, which differ from their good sleeping peers. Associated psychopathology with DSPD includes substance use (i.e., tobacco, alcohol, caffeine), and elevated anxiety and depression symptoms [4 & ,6,7,11] (Micic et al., in preparation) . It is possible that the combination of depression symptoms and short sleep is because of the polymorphism of the 5-HTTLPR genotype [12] ; however, it is yet to be confirmed in young people with DSPD. Poor sleep hygiene has been associated with DSPD (i.e., bedroom presence/bedtime use of electronic media, napping after school) [3 & ,7], although direct comparisons have not yet been performed with matched nonclinical samples. Finally, small trends have been found for DPSD adolescents to be less involved in sport, yet undertaking more extracurricular activities [6] . As sporting matches are often performed on weekend mornings, it may be that sport provides a consistent rise time across the week, disallowing circadian rhythm delays [13] , and thus acts as a protective factor.
THE ETIOLOGICAL BASES FOR DELAYED SLEEP PHASE DISORDER
We now turn our attention to the etiological bases for DSPD before discussing evidence-based treatments. Figure 1 provides an understanding of the possible contributing factors to DSPD.
Reduced homeostatic sleep pressure
A potentially important and overlooked contributor to DSPD is reduced sleep homeostatic pressure
KEY POINTS
The most commonly reported consequences from DSPD include daytime sleepiness that appears to affect school/work performance.
The circadian rhythm length (tau) is significantly longer in patients with DSPD.
Heightened cognitive activity while attempting sleep can be targeted with cognitive-behavior therapy.
Melatonin in the evening and bright light therapy in the morning will help phase advance the delayed circadian rhythm. leading to greater evening alertness [10 & ]. Recent longitudinal analyses of adolescents' EEG have demonstrated reductions in slow-wave sleep that are associated with reduced sleep homeostasis [14, 15] . Recent pioneering research in younger and older good sleeping adolescents shows a longer latency to sleep onset in older adolescents after 14.5-18.5 h of wakefulness [16] . This results in a longer latency to sleep onset from 9:30 p.m. to 1:30 a.m. for older adolescents who rise approximately at 7:00 a.m. [5] . This sleep-onset time lies at the beginning of the 1:00 a.m. to 6:00 a.m. sleeponset range for DSPD [1] . We speculate that adolescents with DSPD may have significantly reduced homeostatic sleep pressure during the day (compared with their good sleeping peers) that would push their sleep onset even later. However, no data to support this hypothesis exist as yet.
Alert

Circadian rhythm abnormalities
Two propositions for circadian abnormalities in DSPD have been provided. The most established idea is that circadian rhythm timing is delayed in individuals with DSPD. Saxvig et al. The second proposition is that the length of the circadian period (tau) is longer in individuals with DSPD compared with good sleepers [18] . A case study of a 30-year-old man in 2007 found a core temperature tau of 25.38 h [19] . Recent data of six young adults (age ¼ 22.0 AE 3.3 years) with DSPD showed a mean core temperature tau of 24.90 h, which was significantly longer than that of the matched good sleepers (tau ¼ 24.48 h) [ 
Sensitivity to evening light and/or insensitivity to morning light
The cause of DSPD may also be explained by an altered response to photic stimuli that is necessary for entrainment to the 24-h day. Because tau is slightly different from 24 h in all humans [18] , adjustments in sleep timing are necessary to synchronize the internal circadian clock to the external 24-h clock. The primary synchronizing stimulus to the circadian system is the daily variation of light and dark. A phase response curve (PRC) to light can explain circadian system shifts, wherein delays occur when light is presented in the evening (beginning of sleep), and advances when light is presented in the morning (end of sleep). There are no published light PRCs for adolescents, though this is the primary aim of one ongoing study [20] , and it remains unknown whether the PRC to light is similar for those with DSPD. Aoki et al. [21] continue to be the only group that has tested light sensitivity in patients with DPSD. Their melatonin suppression data suggested that DSPD patients are more sensitive to phase delaying light. Systematic tests of phase shifting in response to light, however, are still needed in this patient population. DSPD may be an extreme manifestation of the normal delay of sleep and circadian rhythms that emerges during adolescence. One hypothesis is that pubertal adolescents have larger phase delay and smaller phase advance responses compared with adults or younger prepubertal children. If this hypothesis is correct, the adolescent circadian system would shift later more easily, and it would be more difficult to synchronize the endogenous circadian clock to the external 24-h day length. Animal researchers have measured phase shifts in response to a 15-min 150-lux light pulse in pubertal (49 days) and adult (140 days) female mice [22] . These data have been replotted as a PRC separately by age [23] , and illustrated that the phase delay portion of the PRC was greater for the pubertal compared with the adult mice. Data from healthy adolescents also provide preliminary support for a reduced circadian response to morning light [24, 25] . In a more recent study with young adults (ages 18-30 years), who were self-described 'struggling night owls' (and who may have fitted some criteria for DSPD) [26] , participants shifted their sleep earlier for 6 consecutive days. One group was instructed to receive short wavelength light exposure in the mornings shortly after waking up, whereas the other group remained in normal room lighting. Both groups of night owls advanced by about 1.5 h; however, the light group did not advance more than the control group. These data suggest that the morning advancing light was ineffective in these night owls, and/or that the earlier sleep times and reducing the amount of evening (delaying) light may have been more effective than adding morning short wavelength light.
The mechanism by which light sensitivity may change during adolescence, and in particular during puberty, may be driven by gonadal (sex) hormones. Evidence from animal studies demonstrates that gonadal hormones (i.e., androgens and estrogens) can modulate photic sensitivity either through alterations in glutamatergic signaling from the retinohypothalamic tract (RHT) or by modulating the indirect pathways to the central circadian clock, the suprachiasmatic nuclei (SCN) [27] . Gonadal hormones may also act directly on the SCN to modulate responses to photic stimuli, or these hormones may act downstream. No studies to date have examined gonadal hormone levels in DSPD patients; however, one recent study of adult humans reported higher testosterone levels in men who also endorse a later chronotype (i.e., more of an evening type) [28] . Finally, adolescents diagnosed with DSPD have been found to be exposed to more ambient light between 10:00 p.m. and 2:00 a.m. and less light between 8:00 and 9:00 a.m. compared with healthy adolescents [29] . These differences were likely tracking later sleep times in the patients; however, light exposure was similar in the 4 h before sleep onset and 4 h after sleep offset in both the groups. Daily exposure to light and dark relative to a circadian phase marker (i.e., DLMO, core body temperature minimum) may be more informative to test this hypothesis. & ], this provides an opportune time for intrusive unhelpful thinking. Most adolescents seeking treatment for DSPD report racing thoughts in bed while attempting to sleep ($90%) [3 & ], and data from healthy sleep-deprived adolescents show peak intrusive thinking occurs between 4:30 p.m. and 8:30 p.m. [30] . This timing likely corresponds with peak maintenance of alertness, which would occur later for adolescents with delayed sleep timing. Primary concerns in this population include their ability to function academically, followed by the effect of poor sleep on their ability to attend school, and consequences from their peers/ teachers (e.g., shame, embarrassment; Hiller et al., unpublished). The greater number of catastrophizing thoughts is indirectly associated with sleep latency via self-reported anxiety (Hiller et al., unpublished), suggesting a cognitive-emotional-sleeplessness chain of events. These emerging findings suggest that the role of cognition should be considered when understanding, and treating, DSPD in young people. We now review recent clinical trials, beginning with a single treatment component trial, designed to phase advance adolescents' delayed circadian rhythm.
Presleep cognitive activity
TREATMENT OF DELAYED SLEEP PHASE DISORDER IN YOUTH
Van Maanen et al. [8 & ] provided evening melatonin administration (range ¼ 0.1-10 mg, mean ¼ 2.7 mg) to adolescents with DSPD (N ¼ 53). The timing and dose was individually tailored, based on the pretreatment DLMO (mean ¼ 10:32 p.m.AE1:05 h). Treatment began with 1 mg and was increased if no changes were observed after 1 week. After 10 weeks of treatment, adolescents reported significant decrease in chronic sleep reduction, with posttreatment scores moderately lower (d ¼ 0.50) than those of good sleeping adolescents. No sleep and follow-up data were reported, so it is unknown how long this effect as well as the rate of relapse lasted. Although no control was used for melatonin administration (i.e., placebo), this study possessed good ecological validity, and represents a model for sleep disorder clinics. Future controlled studies are needed.
Other clinical trials have used a mixture of treatment components for adolescents' delayed sleep patterns. Abu-Salah and Auger [7] recently reported on the treatments used for 60 adolescent patients (age ¼ 10-20 years) within a 4-year timespan at a sleep medicine clinic. The most common treatment component was 'behavioral sleep interventions' (72%), although it is not known exactly what techniques were used. Evening melatonin administration (65%) and morning bright light therapy (42%) were common, and would, therefore, assist in phase advancing adolescents' circadian rhythm timing. Fifteen percent received zolpidem, likely to address the associated sleep-onset insomnia. Of 22 adolescents at follow-up, eight patients met treatment goals, four received partial success, and 10 a poor treatment outcome. Unfortunately, no information is available as yet regarding the changes in sleep and circadian timing.
Using a randomized controlled design, Gradisar
] evaluated cognitive-behavior therapy (CBT) and bright light therapy to target the sleeponset insomnia and delayed circadian rhythm, respectively, in a group of 49 adolescents (age ¼ 11-18 years) diagnosed with DSPD. CBT included sleep hygiene [i.e., reducing evening stimulation (e.g., caffeine intake, exercise, technology use)], stimulus control therapy instructions (i.e., go to bed when feeling sleepy), and cognitive therapy (i.e., identifying and modifying unhelpful nighttime thoughts). Bright light therapy consisted of the adolescent scheduling natural sunlight and/or broad-spectrum white light ($1000 lux) from a specialized lamp at their usual wake-up time, and advancing light exposure by 30 min each day. Six 50-min sessions were scheduled for over 8 weeks. Compared with the waitlist control group, the treatment group showed large improvements (d >0.80) in various school-night sleep parameters, including sleep-onset latency, sleep-onset time, total sleep time, wake after sleep onset, and rise time. Near large effects (d ¼ 0.71-0.79) were found for daytime functioning, including daytime sleepiness, fatigue, and depression symptoms. At a 6-month follow-up, 15 of the 23 adolescents who underwent treatment still showed improved school-night sleep patterns (d ¼ 0.24-0.72 when comparing pretreatment with 6-month follow-up). Interestingly, daytime functioning effects at the 6-month follow-up had continued to improve, with exhibited large effects (d ¼ 0.86-1.31). Worth noting is that 12% of adolescents withdrew from treatment, and nine could not commit to begin the treatment. Although the prevalence of DSPD is modest, the impact is significant, suggesting interventions that retain as many adolescents as possible are needed.
In summary, melatonin administration appears to be an effective and simple treatment for adolescent DSPD. The more complex combination of CBT and bright light therapy is also effective during posttreatment, and appears to produce long-term benefits. We eagerly await the findings from future clinical trials for DSPD in young people, including a randomized controlled trial of melatonin and light therapy performed on a sample of 60 Norwegian adolescents and young adults (ClinicalTrials.gov NCT00834886) [10 & ], so that the field may better inform clinicians worldwide of the best practice treatments for DSPD in young people.
CONCLUSION
More data are accumulating to form a clinical presentation of DSPD in adolescents and young adults. The cause of DSPD is becoming better understood, although more evidence is needed for sensitivities to evening and morning light. Melatonin administration as a single treatment, and a combination treatment of CBT and morning bright light therapy, are both recommended for alleviating the impact of DSPD. Many more clinical trials are needed, though, to build an evidence base for the treatment of DSPD in youth. This includes not only independent and controlled trials of melatonin, light therapy, and CBT (alone and in combination), but also evaluations of other behavioral (e.g., chronotherapy; scheduled sleep timing) and pharmacological [e.g., methylcobalamin (vitamin B12), zolpidem, triazolam, trazodone] therapies.
